Stay updated on Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.3.4 was added in the page footer, replacing Revision: v3.3.3. This is a minor site update and does not affect the study details or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedAdded a dedicated Locations section with California sites; removed California Locations and the HHS Vulnerability Disclosure link, and updated the page to revision v3.3.3.SummaryDifference0.2%

- Check59 days agoChange DetectedFooter shows Revision: v3.3.2 replacing v3.2.0; no study details, eligibility criteria, or results are altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedRemoved the global government-funding notice about possible delays and operating status. There are no changes to the study details, eligibility criteria, or trial outcomes on the page.SummaryDifference0.4%

- Check81 days agoChange DetectedThe two screenshots show only superficial UI changes to the study page; core study information (title, conditions, eligibility, interventions, outcomes) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check109 days agoChange DetectedCore content updated to reflect a new operating-status notice and a new version (v3.2.0); previous version v3.1.0 removed.SummaryDifference5%

Stay in the know with updates to Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.